Overview
- The prize honors Karl Deisseroth, Peter Hegemann and Georg Nagel for creating optogenetics, a method that gives researchers precise control over targeted cells with light.
- Optogenetics works by inserting genes for microbial light‑activated proteins, such as channelrhodopsins, into selected neurons so those cells fire when exposed to light.
- Researchers have moved the method toward patients by using an AAV gene vector to deliver a red‑shifted channelrhodopsin (ChrimsonR) into retinas and pairing it with light‑stimulation goggles, producing measurable but limited vision gains in small trials and acceptable short‑term safety.
- A parallel path called indirect optogenetics uses knowledge from these cell‑level studies to design drugs that target the same cell types, and those drug programs are advancing into late‑stage trials for conditions such as autism and schizophrenia.
- Key obstacles remain for broader impact—safer and more efficient gene delivery, better light‑delivery hardware, and larger controlled trials—and the Nobel recognition is likely to bring more funding, scrutiny and faster testing of those technical fixes.